Still Hungry on Mounjaro 12.5 mg: Why It Happens and What to Do

What the SURMOUNT trial data tell us about hunger at higher doses

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across tirzepatide doses including 10 mg and 15 mg. Average weight reduction at the 15 mg dose reached around 20–21% over 72 weeks, a figure that reflects the cumulative effect of sustained appetite suppression, not a sudden switch that flips on at a single dose. This matters if you are at 12.5 mg and still hungry, because it suggests appetite control is dose-dependent and incremental. The gap in outcomes between 10 mg and 15 mg was meaningful in the trial, which is part of why 15 mg exists as the ceiling maintenance dose. Reaching 12.5 mg means you are one step away from that ceiling. For many people, the appetite reduction they were hoping for at 10 mg or 12.5 mg becomes more consistent only once 15 mg is established and their body has had several weeks to adjust to it. Hunger at your current dose is not evidence of treatment failure; it may simply be evidence that the full effect is still building. Your prescribing clinician can assess whether that is the most likely explanation in your case.

Why 12.5 mg specifically can feel like a plateau for hunger control

Tirzepatide is a dual GIP and GLP-1 receptor agonist, the only weight-loss medicine licensed in the UK that activates both pathways simultaneously. GLP-1 receptor activation slows gastric emptying and signals fullness to the brain; GIP receptor activation adds a complementary effect on appetite and fat metabolism. At lower doses, one or both of these signals may not be strong enough in a given individual to override the body's habitual hunger patterns, particularly if energy intake is still relatively high or meal composition is not supporting the medicine's action. By 12.5 mg, many people have already noticed significant appetite reduction earlier in their titration, but some find the effect remains partial. The NHS tirzepatide patient information page notes that treatment is titrated gradually to reduce side effects, not because lower doses are therapeutic endpoints in their own right. The 12.5 mg dose is a penultimate step, and for a subset of patients the hunger-suppressing effect simply scales further at 15 mg. The titration schedule exists for tolerability, not because 12.5 mg is where the medicine's appetite work is expected to conclude.

What you can do at 12.5 mg while waiting for your next clinical review

There are practical things within your control that clinical evidence supports alongside GLP-1 treatment. Protein is the most satiating macronutrient per calorie; meals built around lean protein and vegetables (rather than refined carbohydrates) tend to extend the fullness window that tirzepatide creates. Slow eating matters too: gastric emptying is already reduced on tirzepatide, and eating quickly can outpace the stomach's ability to signal fullness to the brain. Hydration is worth checking. Thirst is frequently misread as hunger, and dehydration also increases the perception of appetite. None of this replaces clinical management, but each factor interacts with how well the medicine performs. It is also worth noting when your hunger tends to hit. Persistent hunger in the 24–48 hours before your next weekly injection suggests the medicine's plasma levels are dropping towards the end of the dosing interval, that pattern is different from hunger that is constant throughout the week, and your prescriber will ask about exactly this. If you are wondering whether the pattern you are noticing is common at an earlier stage, you can read about why people are still hungry on Mounjaro 5 mg to understand how appetite suppression can remain incomplete from the very start of titration, which may help you describe your own experience clearly in your next review. If you are curious how the 15 mg step tends to change things, there is a detailed look at what happens to hunger at 15 mg that covers what the trial data and clinical experience suggest.

When to involve your prescriber, and what happens next

Persistent hunger at 12.5 mg is a valid clinical reason to contact your prescribing team. It does not mean you should change your dose without guidance, tirzepatide's licensed schedule runs in four-week steps and dose increases should only follow a clinical assessment. What you should do is report the pattern clearly: when it happens, how intense it is, whether it is changing week to week, and what your current eating and activity habits look like. Your prescriber will also want to check whether any weight loss is continuing despite the hunger, it is entirely possible to still be losing weight while feeling hungrier than you expected, particularly if the hunger is manageable and not leading to significantly increased intake. Reading what other patients on Mounjaro 5 mg have shared about still feeling hungry can give you a useful reference point for how appetite suppression tends to develop across the titration, and may help you articulate your own experience to your prescriber. Dose decisions for a prescription-only medicine belong with a clinician who can see your full picture. For broader context on how tirzepatide works across doses, the Mounjaro treatment overview covers the licensed schedule and what each stage is designed to achieve. You can also read about the hunger experience at the starting dose to understand how appetite suppression typically evolves from the very beginning of treatment. If questions about cost or the service have come up alongside your clinical ones, the treatment page sets out what is included transparently. And if you want to discuss your current treatment or consider an eligibility review with our clinical team, you can check your eligibility at any point, there is no charge for the consultation, and a real prescriber reads every submission the same day it arrives.